Reviva Pharmaceuticals
Monday, February 26, 2024
Royale
CNS/Neurological
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
State
California
Country
United States
Website
http://www.revivapharma.com
CEO/Top Company Official
Dr. Laxminarayan Bhat
Lead Product in Development
Brilaroxazine
Development Phase of Primary Product
Phase III
Number Of Unlicensed Products
Brilaroxazine
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}